Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26053254 | 0.98 | SMN1; SMN2 (0.36) | SMN1; SMN2HDAC3HDAC1HDAC2GAA | |
| SCHEMBL21339358 | 0.95 | SMN1; SMN2 (0.35) | SMN1; SMN2HDAC3HDAC1HDAC2GAA | |
| SCHEMBL22435799 | 0.85 | CNR2 (0.41) | SMN1; SMN2MEN1KMT2ACNR2CNR1 | |
| SCHEMBL30526183 | 0.84 | HSP90AA1 (0.42) | SMN1; SMN2HDAC3HDAC1HDAC2GAA | |
| SCHEMBL21549386 | 0.80 | SLC6A2 (0.38) | CNR1TLR8EPHX2SLC6A2SLC6A4 | |
| SCHEMBL19965715 | 0.80 | SOAT1 (0.34) | HDAC3HDAC1HDAC2CNR2CNR1 | |
| SCHEMBL983682 | 0.79 | ALDH1A1 (0.50) | GAAMEN1KMT2ACNR2CNR1 | |
| SCHEMBL24198892 | 0.79 | HPGD (0.40) | GAACNR2CNR1 | |
| SCHEMBL26655650 | 0.78 | RIPK1 (0.36) | HDAC3HDAC1HDAC2MEN1KMT2A | |
| SCHEMBL22877802 | 0.78 | CNR2 (0.47) | GAACNR2CNR1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220119384-A1 | POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-04-21 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | SMN1; SMN2 2918/4885HDAC3 1549/4885HDAC1 1709/4885 |
| US-20220119384-A1 | POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS | MAVS, VRK1, VRK2 | SMN1; SMN2 2918/4885HDAC3 1549/4885HDAC1 1709/4885 |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | AR, SHBG, BRCA1 | SMN1; SMN2 4764/4885HDAC3 380/4885HDAC1 390/4885 |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | AR, FSHR, ESRRB | SMN1; SMN2 4789/4885HDAC3 277/4885HDAC1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.